

Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

<https://marketpublishers.com/r/R173D8778A27EN.html>

Date: March 2022

Pages: 236

Price: US\$ 4,250.00 (Single User License)

ID: R173D8778A27EN

Abstracts

Global Recombinant Proteins Market projected to be worth USD 2.4 billion by 2030.

According to SPER Market Research, the recombinant proteins market estimated to reach USD 2.4 billion by 2030 with a CAGR of 10.2%. The fuels for the escalation of the market are; the collaboration of industry and academia, expiring of patents of biologic product, growing investments from the government in the pharmaceutical and bio pharmaceutical research and development.

Impact of COVID-19 on the Recombinant Proteins Market

The outbreak of COVID-19 gave an upsurge to the Recombinant Proteins Market; this is due to increase in research and development to reach out the cause of the infection. Companies with product for COVID-19 have a positive expansion.

Scope of the report:

Market size available for years
2019-2030

Base year considered
2021

Forecast period
2022-2030

Segments covered

By Product, By Application, By End-User, By Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

Abcam plc, Abnova Corporation, ACRO Biosystems, Aviva Systems Biology Corporation, Biolegend, Bio-Rad Laboratories, Inc. , Biotech Corporation, BPS Bioscience, Inc., CellGenix GmbH, Enzo Life Sciences, Inc., GenScript, Icosagen AS, Merck KGaA, Miltenyi Biotech, Neuromics, PeproTech, Inc., ProSpec TechnoGene Ltd., Proteintech Group, Inc., ProteoGenix, R&D Systems, RayBiotech Inc, RICHCORE LIFESCIENCES PVT LTD, Sino Biological Inc., STEMCELL Technologies Inc, StressMarq Biosciences Inc, Thermo Fisher Scientific, Inc., United States Biological.

Drivers: increasing government funding and growing Research & Development costs in pharmaceutical & biotechnology companies

Government funding, growing pharmaceutical and biopharmaceuticals research and development are the key factors that drive the escalation of the market.

Restraints: declining price of recombinant Protein

Due to concentration of various market players in the production of recombinant Protein with no varying price; this lead to resist the escalation of the market.

Opportunity: Emerging Economies

Emerging Economies, like Asia Pacific is projected to tender huge opportunities for the players in this market; this is due to rising prevalence of infectious chronic disease, multiple healthcare sector, growing government funding in the research and development of the advanced techniques in proteomic and genomic research, increasing geriatric population, friendly regulatory policies.

Global Recombinant Proteins Market, By Product:

Based on the Product, Global Recombinant Proteins Market is segmented as; Adhesion Molecules and Receptors, Growth Factors and Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, Structural Proteins, Other Recombinant Proteins.

Global Recombinant Proteins Market, By Application:

Based on the Application, Global Recombinant Proteins Market is segmented as; Drug

Discovery & Development (Biologics, Cell & Gene Therapy, Vaccines),
Biopharmaceutical Production, Biotechnology Research, Academic Research Studies,
Other Applications (diagnostics, forensic, and cosmetology applications).

Global Recombinant Proteins Market, By End-User:

Based on the End-User, Global Recombinant Proteins Market is segmented as;
Academic Research Institutes, Biotechnology Companies, Contract Research
Organizations, Pharmaceutical & Biopharmaceutical Companies, Other End Users
[diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent
diagnostic laboratories), forensic laboratories, and the cosmetic industry].

Global Recombinant Proteins Market, By Region:

North America owns the prime share of the market; and this is due to the presence of
top market players, government funding, growing prevalence of infectious and chronic
diseases, growing research and development.

Contents

1. INTRODUCTION

- 1.1. Scope of the report
- 1.2. Market segment analysis

2. RESEARCH METHODOLOGY

- 2.1 Research data source
 - 2.1.1 Secondary data
 - 2.1.2 Primary data
 - 2.1.3 SPER's internal database
 - 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
 - 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

- 4.1. Driver, Restraint, Opportunity and Challenges analysis
 - 4.1.1 Drivers
 - 4.1.2 Restraints
 - 4.1.3 Opportunities
 - 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Recombinant Proteins Market

5. MARKET VARIABLES AND OUTLOOK

- 5.1. SWOT analysis
 - 5.1.1 Strengths
 - 5.1.2 Weaknesses
 - 5.1.3 Opportunities
 - 5.1.4 Threats
- 5.2. PESTEL analysis
 - 5.2.1 Political landscape
 - 5.2.2 Economic landscape

- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
 - 5.3.1 Bargaining power of suppliers
 - 5.3.2 Bargaining power of Buyers
 - 5.3.3 Threat of Substitute
 - 5.3.4 Threat of new entrant
 - 5.3.5 Competitive rivalry
- 5.4. Heat map analysis

6. GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2019-2030 (USD MILLION)

- 6.1. Adhesion Molecules and Receptors
- 6.2. Growth Factors and Chemokines
- 6.3. Immune Response Proteins
- 6.4. Kinase Proteins
- 6.5. Membrane Proteins
- 6.6. Recombinant Metabolic Enzymes
- 6.7. Regulatory Proteins
- 6.8. Structural Proteins
- 6.9. Other Recombinant Proteins

7. GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2019-2030 (USD MILLION)

- 7.1. Drug Discovery & Development
 - 7.1.1. Biologics
 - 7.1.2. Cell & Gene Therapy
 - 7.1.3. Vaccines
- 7.2. Biopharmaceutical Production
- 7.3. Biotechnology Research
- 7.4. Academic Research Studies
- 7.5. Other Applications (diagnostics, forensic, and cosmetology applications)

8. GLOBAL RECOMBINANT PROTEINS MARKET, BY END-USER, 2019-2030 (USD MILLION)

- 8.1. Academic Research Institutes
- 8.2. Biotechnology Companies
- 8.3. Contract Research Organizations
- 8.4. Pharmaceutical & Biopharmaceutical Companies
- 8.5. Other End Users [diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent diagnostic laboratories), forensic laboratories, and the cosmetic industry]

9. GLOBAL RECOMBINANT PROTEINS MARKET, BY REGION, 2019-2030 (USD MILLION)

- 9.1. North America
 - 9.1.1. United States
 - 9.1.2. Canada
 - 9.1.3. Mexico
- 9.2. Europe
 - 9.2.1. Germany
 - 9.2.2. United Kingdom
 - 9.2.3. France
 - 9.2.4. Italy
 - 9.2.5. Spain
 - 9.2.6. Rest of Europe
- 9.3. Asia-Pacific
 - 9.3.1. China
 - 9.3.2. Japan
 - 9.3.3. India
 - 9.3.4. Australia
 - 9.3.5. South Korea
 - 9.3.6. Rest of Asia-Pacific
- 9.4. South America
 - 9.4.1. Brazil
 - 9.4.2. Argentina
 - 9.4.3. Rest of South America
- 9.5. Middle East & Africa
 - 9.5.1. Kingdom of Saudi Arabia
 - 9.5.2. United Arab Emirates
 - 9.5.3. Rest of Middle East & Africa

10. COMPANY PROFILES

10.1. Abcam plc

- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments

10.2. Abnova Corporation

- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments

10.3. ACRO Biosystems

- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments

10.4. Aviva Systems Biology Corporation

- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments

10.5. Biolegend

- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments

10.6. Bio-Rad Laboratories, Inc.

- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments

10.7. Biotech Corporation

- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments

10.8. BPS Bioscience, Inc.

- 10.8.1. Company details

- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
- 10.9. CellGenix GmbH
 - 10.9.1. Company details
 - 10.9.2. Financial outlook
 - 10.9.3. Product summary
 - 10.9.4. Recent developments
- 10.10. Enzo Life Sciences, Inc.
 - 10.10.1. Company details
 - 10.10.2. Financial outlook
 - 10.10.3. Product summary
 - 10.10.4. Recent developments
- 10.11. GenScript
 - 10.11.1 Company details
 - 10.11.2 Financial outlook
 - 10.11.3 Product summary
 - 10.11.4 Recent developments
- 10.12. Icosagen AS
 - 10.12.1. Company details
 - 10.12.2. Financial outlook
 - 10.12.3. Product summary
 - 10.12.4. Recent developments
- 10.13. Merck KGaA
 - 10.13.1. Company details
 - 10.13.2. Financial outlook
 - 10.13.3. Product summary
 - 10.13.4. Recent developments
- 10.14. Miltenyi Biotech
 - 10.14.1. Company details
 - 10.14.2. Financial outlook
 - 10.14.3. Product summary
 - 10.14.4. Recent developments
- 10.15. Neuromics
 - 10.15.1. Company details
 - 10.15.2. Financial outlook
 - 10.15.3. Product summary
 - 10.15.4. Recent developments
- 10.16. PeproTech, Inc.

- 10.16.1. Company details
- 10.16.2. Financial outlook
- 10.16.3. Product summary
- 10.16.4. Recent developments
- 10.17. ProSpec TechnoGene Ltd.
 - 10.17.1. Company details
 - 10.17.2. Financial outlook
 - 10.17.3. Product summary
 - 10.17.4. Recent developments
- 10.18. Proteintech Group, Inc.
 - 10.18.1. Company details
 - 10.18.2. Financial outlook
 - 10.18.3. Product summary
 - 10.18.4. Recent developments
- 10.19. ProteoGenix
 - 10.19.1. Company details
 - 10.19.2. Financial outlook
 - 10.19.3. Product summary
 - 10.19.4. Recent developments
- 10.20. R&D Systems
 - 10.20.1. Company details
 - 10.20.2. Financial outlook
 - 10.20.3. Product summary
 - 10.20.4. Recent developments
- 10.21. RayBiotech Inc.
 - 10.21.1. Company details
 - 10.21.2. Financial outlook
 - 10.21.3. Product summary
 - 10.21.4. Recent developments
- 10.22. Richcore Lifesciences Pvt Ltd
 - 10.22.1. Company details
 - 10.22.2. Financial outlook
 - 10.22.3. Product summary
 - 10.22.4. Recent developments
- 10.23. Sino Biological Inc.
 - 10.23.1. Company details
 - 10.23.2. Financial outlook
 - 10.23.3. Product summary
 - 10.23.4. Recent developments

10.24. STEMCELL Technologies Inc

10.24.1. Company details

10.24.2. Financial outlook

10.24.3. Product summary

10.24.4. Recent developments

10.25. StressMarq Biosciences Inc

10.25.1. Company details

10.25.2. Financial outlook

10.25.3. Product summary

10.25.4. Recent developments

10.26. Thermo Fisher Scientific, Inc.

10.26.1. Company details

10.26.2. Financial outlook

10.26.3. Product summary

10.26.4. Recent developments

10.27. United States Biological

10.27.1. Company details

10.27.2. Financial outlook

10.27.3. Product summary

10.27.4. Recent developments

I would like to order

Product name: Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Product link: <https://marketpublishers.com/r/R173D8778A27EN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R173D8778A27EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

